KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

Jian Ming Xu; Xiao Jing Liu; Fei Jiao Ge; Li Lin; Yan Wang; Manish R. Sharma; Ze Yuan Liu; Stefania Tommasi; Angelo Paradiso

doi:10.1186/s13046-014-0104-7

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

Jian Ming Xu, Xiao Jing Liu, Fei Jiao Ge, Li Lin, Yan Wang, Manish R. Sharma, Ze Yuan Liu, Stefania Tommasi, Angelo Paradiso

IRCCS Giovanni Paolo II

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic-predictive relevance of KRAS status, determined in tumor and plasma DNA by two different assays, in a large mono-institutional series of mCRC patients.

METHODS: DNA sequencing and peptide-nucleic-acid-mediated-polymerase chain reaction clamping (PNA-PCR) were used to determine KRAS status in 416 tumor and 242 matched plasma DNA samples from mCRC patients who received chemotherapy only. Relationships with outcomes were analyzed with respect to the different assays and tissue types.

RESULTS: PNA-PCR was significantly more sensitive in detecting KRAS mutations than sequencing (41% vs. 30%, p

CONCLUSIONS: KRAS mutation status is of prognostic relevance in patients with mCRC. KRAS mutations in both tumor tissue and plasma are a strong prognostic marker for poor outcomes.

Original language	English
Pages (from-to)	104
Number of pages	1
Journal	Journal of Experimental and Clinical Cancer Research
Volume	33
DOIs	https://doi.org/10.1186/s13046-014-0104-7
Publication status	Published - 2014

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1186/s13046-014-0104-7

Cite this

@article{3bf1536cbeec4352a1e4addfca9fcc16,

title = "KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer",

abstract = "BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic-predictive relevance of KRAS status, determined in tumor and plasma DNA by two different assays, in a large mono-institutional series of mCRC patients.METHODS: DNA sequencing and peptide-nucleic-acid-mediated-polymerase chain reaction clamping (PNA-PCR) were used to determine KRAS status in 416 tumor and 242 matched plasma DNA samples from mCRC patients who received chemotherapy only. Relationships with outcomes were analyzed with respect to the different assays and tissue types.RESULTS: PNA-PCR was significantly more sensitive in detecting KRAS mutations than sequencing (41% vs. 30%, p CONCLUSIONS: KRAS mutation status is of prognostic relevance in patients with mCRC. KRAS mutations in both tumor tissue and plasma are a strong prognostic marker for poor outcomes.",

author = "Xu, {Jian Ming} and Liu, {Xiao Jing} and Ge, {Fei Jiao} and Li Lin and Yan Wang and Sharma, {Manish R.} and Liu, {Ze Yuan} and Stefania Tommasi and Angelo Paradiso",

year = "2014",

doi = "10.1186/s13046-014-0104-7",

language = "English",

volume = "33",

pages = "104",

journal = "Journal of Experimental and Clinical Cancer Research",

issn = "0392-9078",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

AU - Xu, Jian Ming

AU - Liu, Xiao Jing

AU - Ge, Fei Jiao

AU - Lin, Li

AU - Wang, Yan

AU - Sharma, Manish R.

AU - Liu, Ze Yuan

AU - Tommasi, Stefania

AU - Paradiso, Angelo

PY - 2014

Y1 - 2014

N2 - BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic-predictive relevance of KRAS status, determined in tumor and plasma DNA by two different assays, in a large mono-institutional series of mCRC patients.METHODS: DNA sequencing and peptide-nucleic-acid-mediated-polymerase chain reaction clamping (PNA-PCR) were used to determine KRAS status in 416 tumor and 242 matched plasma DNA samples from mCRC patients who received chemotherapy only. Relationships with outcomes were analyzed with respect to the different assays and tissue types.RESULTS: PNA-PCR was significantly more sensitive in detecting KRAS mutations than sequencing (41% vs. 30%, p CONCLUSIONS: KRAS mutation status is of prognostic relevance in patients with mCRC. KRAS mutations in both tumor tissue and plasma are a strong prognostic marker for poor outcomes.

AB - BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic-predictive relevance of KRAS status, determined in tumor and plasma DNA by two different assays, in a large mono-institutional series of mCRC patients.METHODS: DNA sequencing and peptide-nucleic-acid-mediated-polymerase chain reaction clamping (PNA-PCR) were used to determine KRAS status in 416 tumor and 242 matched plasma DNA samples from mCRC patients who received chemotherapy only. Relationships with outcomes were analyzed with respect to the different assays and tissue types.RESULTS: PNA-PCR was significantly more sensitive in detecting KRAS mutations than sequencing (41% vs. 30%, p CONCLUSIONS: KRAS mutation status is of prognostic relevance in patients with mCRC. KRAS mutations in both tumor tissue and plasma are a strong prognostic marker for poor outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84965191195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965191195&partnerID=8YFLogxK

U2 - 10.1186/s13046-014-0104-7

DO - 10.1186/s13046-014-0104-7

M3 - Article

C2 - 25491325

AN - SCOPUS:84965191195

SN - 0392-9078

VL - 33

SP - 104

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

ER -

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this